Breaking News Instant updates and real-time market news.

XNET

Xunlei

$13.28

-0.11 (-0.82%)

, GNC

GNC Holdings

$3.72

-0.05 (-1.33%)

08:45
12/26/17
12/26
08:45
12/26/17
08:45

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Xunlei (XNET) 61.78% +6.57, GNC Holdings (GNC) 24.64% +3.09, Sears (SHLD) 85.45% +1.53, Enterprise Products (EPD) 0.86% +0.61, Euro ETF (FXE) 2.83% +0.34, Market Vectors Semiconductor (SMH) 1.39% +0.25, Utilities Sector SPDR (XLU) 0.99% +0.25, MannKind (MNKD) 46.46% +0.21, Allergan (AGN) 0.37% +0.12, and Direxion Daily Smal Cap Bull 3X Shares (TNA) 3.64% +0.11.

XNET

Xunlei

$13.28

-0.11 (-0.82%)

GNC

GNC Holdings

$3.72

-0.05 (-1.33%)

SHLD

Sears

$3.76

-0.02 (-0.53%)

EPD

Enterprise Products

$26.40

0.3 (1.15%)

FXE

Euro Currency Trust

$114.24

-0.19 (-0.17%)

SMH

Market Vectors Semiconductor

$99.16

0.04 (0.04%)

XLU

Utilities SPDR

$52.45

0.08 (0.15%)

MNKD

MannKind

$2.41

-0.11 (-4.37%)

AGN

Allergan

$164.90

-2.73 (-1.63%)

TNA

Terra Nova (Bermuda) Holdings

$71.33

-0.41 (-0.57%)

  • 08

    Jan

  • 22

    Jan

  • 16

    Feb

  • 25

    Mar

XNET Xunlei
$13.28

-0.11 (-0.82%)

GNC GNC Holdings
$3.72

-0.05 (-1.33%)

01/19/17
GSCO
01/19/17
DOWNGRADE
GSCO
Sell
GNC Holdings downgraded to Sell from Neutral at Goldman
01/19/17
GSCO
01/19/17
DOWNGRADE
GSCO
Sell
GNC Holdings downgraded to Sell on brand re-launch, competition at Goldman
As previously reported, Goldman downgraded GNC Holdings to Sell from Neutral and lowered its price target to $8 from $12. Analyst Stephen Tanal believes GNC's brand re-launch, which it cut prices meaningfully across half of its assortment and ended its Gold Card loyalty program, will weigh on profitability to a much greater degree than consensus estimates reflect. The analyst expects persistent same-store-sales declines to persist given share losses to conventional retailers including grocers, drug stores, warehouse/clubs, as well as online challengers.
02/15/17
MACQ
02/15/17
NO CHANGE
Target $20
MACQ
Outperform
GNC Holdings shares pricing in 'draconian' outcomes, says Macquarie
Macquarie analyst Bob Summers said GNC Holdings' Q4 and near-term results will prove challenging but management has made decisions that will significantly increase the company's long-term potential to succeed by simplifying pricing and having consistent in-store and online pricing. The analyst said these efforts will pressure margins, but shares are pricing in "draconian" outcomes with shares trading at just over 4x P/E. Summers expects free cash flow to remain positive, which could be further enhanced by cutting the dividend and notes there are no near-term debt maturities to create credit risk. The analyst said even a "slight bend" in same-store sales trends could produce a dramatic positive outcome and reiterates his Outperform rating and $20 price target on GNC Holdings.
04/19/17
JPMS
04/19/17
NO CHANGE
Target $12
JPMS
Neutral
GNC Holdings price target raised to $12 from $10 at JPMorgan
JPMorgan analyst Christopher Horvers raised his price target for GNC Holdings to $12 saying yesterday's earnings and comp beat "take off the table the terminal value question that many investors were focused on." The question, however, is if the traffic is sustainable and whether GNC can turn the decline in average ticket up, Horvers tells investors in a post-earnings research note. The analyst keeps a Neutral rating on the shares.
SHLD Sears
$3.76

-0.02 (-0.53%)

12/22/17
MSCO
12/22/17
NO CHANGE
MSCO
TJX stands to benefit from Bon-Ton closures, says Morgan Stanley
After analyzing which department stores and off-price retailers have the greatest overlap with troubled retailer Bon-Ton Stores (BONT), Morgan Stanley analyst Kimberly Greenberger found that over 40% of Bon-Ton's have a TJX (TJX) concept within a one mile radius and she sees it as the retailer that could benefit the most from a Bon-Ton liquidity event. Though Sears (SHLD) has the greatest overlap overall, there is no evidence to suggest it, nor Kohl's (KSS) and J.C. Penney (JCP), have been able to capitalize on Bon-Ton's struggles so far, added Greenberger.
12/04/17
MOFT
12/04/17
INITIATION
MOFT
Sell
Sears initiated with a Sell at MoffettNathanson
12/01/17
SUSQ
12/01/17
NO CHANGE
Target $3
SUSQ
Negative
Sears doubtful to remain a going concern, says Susquehanna
Susquehanna analyst Bill Dreher said Sears will continue to pare assets, reduce expenses, and lower head count in its attempt to survive, but he noted the amount of saleable assets is finite and its sales continue to fall faster than expenses. He remains concerned about the company's ability to remain a going concern. Dreher reiterated his Negative rating and lowered his price target to $3 from $4 on Sears shares.
10/24/17
LOOP
10/24/17
NO CHANGE
Target $72
LOOP
Buy
Whirlpool leaving Sears positive for Best Buy, says Loop Capital
Loop Capital analyst Anthony Chukumba views Whirlpool (WHR) no longer offering appliances in Sears (SHLD) stores or online as "another incremental positive" for Best Buy (BBY). While picking up Whirlpool sales will have a "relatively insignificant impact" on Best Buy's annual earnings, Sears can no longer claim it carries all of the major U.S. appliance brands, which should accelerate its market share losses, Chukumba tells investors in a research note. He thinks Sears is "inching closer and closer" to a bankruptcy and reiterates a Buy rating on Best Buy with a $72 price target. The stock in morning trading is up 87c to $56.89.
EPD Enterprise Products
$26.40

0.3 (1.15%)

06/15/17
MSCO
06/15/17
UPGRADE
MSCO
Overweight
Enterprise Products upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst Tom Abrams upgraded Enterprise Products to Overweight from Equal Weight citing relative valuation and said the company should benefit from improving ethane markets over the next few years.
06/15/17
06/15/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. La Quinta (LQ) upgraded to Overweight from Equal Weight at Morgan Stanley with the firm's analyst indicating a more bullish outlook for lodging demand given the stronger economy and raised La Quinta estimates, and notes shares have underperformed year-to-date. 2. Paccar (PCAR) upgraded to Buy from Neutral at Goldman Sachs with analyst Jerry Revinch saying he is positive on the company's prospects to further improve its industry-leading returns on capital. 3. Thomson Reuters (TRI) upgraded to Outperform from Neutral at Macquarie with analyst Giasone Salati saying he now believes the company is well positioned for what might be a once-in-a-decade boost in demand for services by MIFID II investment firms. 4. Beazer Homes (BZH) upgraded to Outperform from Neutral at Wedbush with analyst Jay McCanless citing what he sees as "the loosening of credit standards at Fannie Mae (FNMA)." 5. Enterprise Products (EPD) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Tom Abrams citing relative valuation and said the company should benefit from improving ethane markets over the next few years. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/13/17
TUDR
12/13/17
UPGRADE
TUDR
Buy
Enterprise Products upgraded to Buy from Hold at Tudor Pickering
10/10/17
GHSC
10/10/17
INITIATION
Target $29
GHSC
Neutral
Enterprise Products initiated with a Neutral at Seaport Global
Seaport Global analyst Bernie Colson initiated Enterprise Products with a Neutral and $29 price target.
FXE Euro Currency Trust
$114.24

-0.19 (-0.17%)

SMH Market Vectors Semiconductor
$99.16

0.04 (0.04%)

XLU Utilities SPDR
$52.45

0.08 (0.15%)

MNKD MannKind
$2.41

-0.11 (-4.37%)

11/01/17
MAXM
11/01/17
DOWNGRADE
MAXM
Hold
Maxim wanted bigger capital raise, downgrades MannKind to Hold
Maxim analyst Jason Kolbert downgraded MannKind to Hold from Buy saying he believes the company has less than two operating quarters of cash on hand. Mannkind will spend just under $100M per year for the next few years to support Afrezza, Kolbert tells investors in an intraday research note. He estimates the company will end the year with around $60M in cash. The analyst thought the recent capital raise would have been larger to "get the Afrezza launch off the ground." The inhaled insulin is both a promotionally sensitive and an educationally-driven product, Kolbert argues. He believes MannKind's recent equity offering does not provide adequate funds to "translate into meaningful signs that the launch of Afrezza will be successful." MannKind in afternoon trading is down 19c to $3.10. Kolbert does not have a target for the shares.
11/01/17
MAXM
11/01/17
DOWNGRADE
MAXM
Hold
MannKind downgraded to Hold from Buy at Maxim
10/24/17
HCWC
10/24/17
NO CHANGE
Target $7
HCWC
Buy
MannKind improved near-term liquidity position, says H.C. Wainwright
H.C. Wainwright analyst Oren Livnat says MannKind yesterday improved its near-term liquidity position by pushing out, and likely converting to equity, the $10M immediately due to Deerfield, and pushed out the 2018 convert maturity to 2021. The "likely modest dilution" is worth it to ensure cash is better used to support the Afrezza launch, Livnat tells investors in a research note. Further, after MannKind's Brazilian partner submitted the Afrezza dossier, the analyst notes Brazil is a top-five diabetes market that could potentially be a "material contributor." Livnat reiterates a Buy rating on MannKind with a $7 price target.
10/10/17
HCWC
10/10/17
INITIATION
Target $7
HCWC
Buy
MannKind initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Oren Livnat started MannKind with a Buy rating and $7 price target. The shares closed yesterday up 30c to $5.33. The "game-changing" new label approved last week will allow Afrezza to gain a footing in the "very large insulin space and become the significant product that its innovation merits," Livnat tells investors in a research note. The analyst expects MannKind, under new management, to soon recapitalize and eventually accelerate Afrezza growth to peak sales more than $725M in the U.S.
AGN Allergan
$164.90

-2.73 (-1.63%)

12/07/17
ARGS
12/07/17
DOWNGRADE
ARGS
Hold
Allergan downgraded to Hold at Argus on growing threats of competition
As noted earlier, Argus analyst David Toung downgraded Allergan (AGN) to Hold from Buy. Toung says the company's Botox may face increasing competition from a botulinum toxin-based product being developed by Revance Therapeutics (RVNC) by 2020. The analyst also notes that Allergan's Restasis dry-eye treatment could be challenged by generics by the middle of next year after a U.S. court ruling invalidated its patent protection.
12/07/17
12/07/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Yelp (YELP) downgraded to Underweight from Neutral at Piper Jaffray with analyst Sam Kemp saying given the "messiness" of removing Eat24, investors missed that Yelp lowered organic fourth quarter guidance by 2%. 2. Toll Brothers (TOL) downgraded to Outperform from Strong Buy at Raymond James with analyst Buck Horne saying fiscal 2018 gross margins are more cautious than expected due to New York City headwinds ahead of an upcoming supply wave. 3. Priceline (PCLN) and Expedia (EXPE) were downgraded to Neutral from Buy at MKM Partners. 4. Ctrip.com (CTRP) downgraded to Neutral from Overweight at JPMorgan with analyst Alex Yao saying the introduced an opt-in option in early October by removing part of the default purchase setting of bundled products. 5. Allergan (AGN) downgraded to Hold from Buy at Argus analyst David Toung saying the company's Botox may face increasing competition from a botulinum toxin-based product being developed by Revance Therapeutics (RVNC) by 2020. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/08/17
RHCO
12/08/17
NO CHANGE
Target $53
RHCO
Buy
Revance price target raised to $53 from $32 at SunTrust
SunTrust analyst John Boris raised his price target on Revance (RVNC) to $53, saying the company's RT002's clinical data is "de-risked in glabellar lines", offering significant differentiation relative to Allegan's (AGN) Botox. Boris expects GL SAKURA data to be presented in February of 2018, modeling approval by the first half of 2020. The analyst also notes that the RT0002 Phase-2 plantar fasciitis data on track for December and the initiation of Phase 3 cervical dystonia trials for Q2 of next year, keeping his Buy rating on the stock.
12/19/17
FBCO
12/19/17
NO CHANGE
Target $214
FBCO
Outperform
Allergan price target lowered to $214 from $224 at Credit Suisse
Credit Suisse analyst Vamil Divan price target lowered to $214 from $224 following the company's disappointing performance during the latter part of 2017. The analyst notes that questions around base business and effect of LOEs have impacted stock, but expectations and valuation are now more reasonable. Divan reiterates an Outperform rating on the shares.
TNA Terra Nova (Bermuda) Holdings
$71.33

-0.41 (-0.57%)

TODAY'S FREE FLY STORIES

HCLP

Hi-Crush Partners

$13.20

-0.825 (-5.88%)

17:54
05/25/18
05/25
17:54
05/25/18
17:54
Hot Stocks
Hi-Crush Partners provides update on bulldozer incident in Whitehall facility »

Hi-Crush Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

POST

Post Holdings

$77.98

1.49 (1.95%)

17:37
05/25/18
05/25
17:37
05/25/18
17:37
Hot Stocks
Post Holdings reports fire in Michael Foods' plant in Pennsylvania »

Post Holdings reported a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

ABMD

Abiomed

$394.49

0.04 (0.01%)

, WYN

Wyndham

$107.98

-0.58 (-0.53%)

17:34
05/25/18
05/25
17:34
05/25/18
17:34
Hot Stocks
Abiomed to enter S&P 500 index on May 31 »

S&P MidCap 400…

ABMD

Abiomed

$394.49

0.04 (0.01%)

WYN

Wyndham

$107.98

-0.58 (-0.53%)

MSCC

Microsemi

$68.74

0.005 (0.01%)

PRAH

PRA Health

$81.19

0.33 (0.41%)

GME

GameStop

$12.64

-0.1 (-0.78%)

FRED

Fred's

$1.69

0.05 (3.05%)

PRSP

Symbol now PB

$0.00

(0.00%)

RRTS

Roadrunner

$2.19

0.04 (1.86%)

DXC

DXC Technology

$94.20

-5.42 (-5.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 31

    May

  • 05

    Jun

  • 12

    Jun

PRAH

PRA Health

$81.19

0.33 (0.41%)

, ABMD

Abiomed

$394.49

0.04 (0.01%)

17:24
05/25/18
05/25
17:24
05/25/18
17:24
Hot Stocks
Breaking Hot Stocks news story on PRA Health, Abiomed »

PRA Health to replace…

PRAH

PRA Health

$81.19

0.33 (0.41%)

ABMD

Abiomed

$394.49

0.04 (0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 05

    Jun

  • 12

    Jun

WYN

Wyndham

$107.98

-0.58 (-0.53%)

, MSCC

Microsemi

$68.74

0.005 (0.01%)

17:23
05/25/18
05/25
17:23
05/25/18
17:23
Hot Stocks
Breaking Hot Stocks news story on Wyndham, Microsemi »

Wyndham to replace…

WYN

Wyndham

$107.98

-0.58 (-0.53%)

MSCC

Microsemi

$68.74

0.005 (0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABMD

Abiomed

$394.49

0.04 (0.01%)

, WYN

Wyndham

$107.98

-0.58 (-0.53%)

17:21
05/25/18
05/25
17:21
05/25/18
17:21
Hot Stocks
Breaking Hot Stocks news story on Abiomed, Wyndham »

ABIOMED to replace…

ABMD

Abiomed

$394.49

0.04 (0.01%)

WYN

Wyndham

$107.98

-0.58 (-0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 05

    Jun

  • 12

    Jun

PCG

PG&E

$44.67

0.84 (1.92%)

17:16
05/25/18
05/25
17:16
05/25/18
17:16
Periodicals
CA Forestry Dept rules PG&E equipment responsible for wildfires, Bloomberg says »

Report filed by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FARM

Farmer Bros.

$28.50

0.15 (0.53%)

17:09
05/25/18
05/25
17:09
05/25/18
17:09
Hot Stocks
Levin Capital Strategies reports 8.4% stake in Farmer Bros »

Levin Capital purchased…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NDLS

Noodles & Company

$8.90

-0.35 (-3.78%)

17:07
05/25/18
05/25
17:07
05/25/18
17:07
Syndicate
Breaking Syndicate news story on Noodles & Company »

Noodles & Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WIN

Windstream

$1.22

-0.125 (-9.29%)

17:06
05/25/18
05/25
17:06
05/25/18
17:06
Hot Stocks
Windstream completes one-for-five reverse stock split »

Windstream completed its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NDLS

Noodles & Company

$8.90

-0.35 (-3.78%)

17:06
05/25/18
05/25
17:06
05/25/18
17:06
Syndicate
Breaking Syndicate news story on Noodles & Company »

Noodles & Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPD

Enterprise Products

$27.87

-0.12 (-0.43%)

17:01
05/25/18
05/25
17:01
05/25/18
17:01
Hot Stocks
Enterprise Products conduts open season for West Texas Crude oil expansion »

Enterprise Products…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INO

Inovio

$4.89

0.06 (1.24%)

16:37
05/25/18
05/25
16:37
05/25/18
16:37
Syndicate
Breaking Syndicate news story on Inovio »

Inovio files $250M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCII

Rent-A-Center

$10.14

0.13 (1.30%)

16:36
05/25/18
05/25
16:36
05/25/18
16:36
Hot Stocks
Rent-A-Center 16.8% shareholder Engaged Capital nominates Carol McFate to Board »

On May 25, 2018, Engaged…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKER

Akers Biosciences

$0.59

0.0086 (1.48%)

16:34
05/25/18
05/25
16:34
05/25/18
16:34
Hot Stocks
Akers Biosciences receives delinquency notice from NASDAQ »

Akers Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DHCP

Ditech

$6.60

0.37 (5.94%)

16:31
05/25/18
05/25
16:31
05/25/18
16:31
Hot Stocks
Ditech discloses receipt of late filing notice from NYSE »

Ditech Holding announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPS

Gap

$28.15

-4.82 (-14.62%)

, FL

Foot Locker

$55.97

9.585 (20.67%)

16:30
05/25/18
05/25
16:30
05/25/18
16:30
General news
On The Fly: Top stock stories for Friday »

Stocks on Wall Street…

GPS

Gap

$28.15

-4.82 (-14.62%)

FL

Foot Locker

$55.97

9.585 (20.67%)

HLF

Herbalife Nutrition

$48.76

-5.09 (-9.45%)

IEP

Icahn Enterprises

$69.41

0.22 (0.32%)

FCAU

Fiat Chrysler

$21.82

-0.445 (-2.00%)

DGX

Quest Diagnostics

$105.89

5 (4.96%)

UNH

UnitedHealth

$244.96

2.23 (0.92%)

ROST

Ross Stores

$77.35

-5.6 (-6.75%)

ADSK

Autodesk

$132.80

-5.96 (-4.30%)

AAL

American Airlines

$44.89

1.34 (3.08%)

LUV

Southwest

$52.86

1.65 (3.22%)

DAL

Delta Air Lines

$55.89

1.48 (2.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    May

  • 30

    May

  • 30

    May

  • 12

    Jun

  • 13

    Jun

  • 14

    Jun

  • 26

    Jun

  • 29

    Jun

16:30
05/25/18
05/25
16:30
05/25/18
16:30
Options
Preliminary option volume of 16.4M today »

Preliminary option volume…

VTL

Vital Therapies

$5.65

-0.475 (-7.76%)

16:26
05/25/18
05/25
16:26
05/25/18
16:26
Syndicate
Breaking Syndicate news story on Vital Therapies »

Vital Therapies files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

VTL

Vital Therapies

$5.65

-0.475 (-7.76%)

16:26
05/25/18
05/25
16:26
05/25/18
16:26
Syndicate
Breaking Syndicate news story on Vital Therapies »

Vital Therapies files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

LNC

Lincoln National

$68.89

-0.555 (-0.80%)

16:24
05/25/18
05/25
16:24
05/25/18
16:24
Syndicate
Breaking Syndicate news story on Lincoln National »

Lincoln National files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DGLY

Digital Ally

$2.63

0.075 (2.94%)

16:23
05/25/18
05/25
16:23
05/25/18
16:23
Syndicate
Breaking Syndicate news story on Digital Ally »

Digital Ally files $25M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNGX

Soligenix

$1.58

-0.005 (-0.32%)

16:23
05/25/18
05/25
16:23
05/25/18
16:23
Syndicate
Breaking Syndicate news story on Soligenix »

Soligenix files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HF

HFF Inc.

$35.34

0.08 (0.23%)

16:21
05/25/18
05/25
16:21
05/25/18
16:21
Hot Stocks
HFF Inc. announces $640M sale of 5 Bryant Park office tower in Manhattan »

HFF announces the $640M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 31

    May

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
05/25/18
05/25
16:20
05/25/18
16:20
Options
Closing CBOE SPX and VIX Index summary for May 25th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.